Trajectories of estradiol and follicle-stimulating hormone over the menopause transition and early markers of atherosclerosis after menopause

European Journal of Preventive Cardiology

Volumn 23, Issue 7, 2016, Pages 694-703

  El Khoudary, Samar R ^a   Santoro, Nanette ^b   Chen, Hsiang Yu ^a   Tepper, Ping G ^a   Brooks, Maria M ^a   Thurston, Rebecca C ^a,c   Janssen, Imke ^d   Harlow, Sioban D ^e   Barinas Mitchell, Emma ^a   Selzer, Faith ^a   Derby, Carol A ^f   Jackson, Elizabeth A ^g   McConnell, Daniel ^e   Matthews, Karen A ^a,c  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d RUSH UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF MICHIGAN   (United States)

^f ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^g UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

atherosclerosis; epidemiology; Estradiol; intima media thickness; menopause; women

Indexed keywords

ESTRADIOL; FOLLITROPIN; GLUCOSE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; BIOLOGICAL MARKER;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CAROTID ARTERY; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; COMMON CAROTID ARTERY; DISEASE ASSOCIATION; ESTRADIOL BLOOD LEVEL; FEMALE; FOLLICULAR PHASE; FOLLITROPIN BLOOD LEVEL; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSE; MENSTRUAL CYCLE; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; AGING; ASIAN AMERICAN; BLOOD; CAUCASIAN; CLINICAL TRIAL; EPIDEMIOLOGY; ETHNOLOGY; HISPANIC; MIDDLE AGED; MULTICENTER STUDY; RISK FACTOR; UNITED STATES;

ADULT; AGING; ASIAN AMERICANS; ATHEROSCLEROSIS; BIOMARKERS; CAROTID INTIMA-MEDIA THICKNESS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FOLLICLE STIMULATING HORMONE; FOLLOW-UP STUDIES; HISPANIC AMERICANS; HUMANS; MENOPAUSE; MIDDLE AGED; RISK FACTORS; UNITED STATES;

EID: 84962449910     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1177/2047487315607044     Document Type: Article

References (42)

1. Randolph JF Jr, Zheng H, Sowers MR, et al. Change in follicle-stimulating hormone and estradiol across the menopausal transition: Effect of age at the final menstrual period. J Clin Endocrinol Metab 2011; 96: 746-754.
2. Mozaffarian D, Benjamin EJ, Go AS, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2015 update: A report from the American Heart Association. Circulation 2015; 131: e29-e322.
3. Gorodeski GI,. Impact of the menopause on the epidemiology and risk factors of coronary artery heart disease in women. Exp Gerontol 1994; 29: 357-375.
4. Psaty BM, Heckbert SR, Atkins D, et al. The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women. Arch Intern Med 1994; 154: 1333-1339.
5. Grodstein F, Stampfer MJ, Manson JE, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996; 335: 453-461.
6. Grodstein F, Manson JE, Colditz GA, et al. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000; 133: 933-941.
7. Henderson BE, Paganini-Hill A, Ross RK,. Decreased mortality in users of estrogen replacement therapy. Arch Intern Med 1991; 151: 75-78.
8. Prentice RL, Langer RD, Stefanick ML, et al.Women's Health Initiative Investigators,. Combined analysis of Women's Health Initiative observational and clinical trial data on postmenopausal hormone treatment and cardiovascular disease. Am J Epidemiol 2006; 163: 589-599.
9. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progesterone Replacement Study (HERS) Research Group. JAMA 1998; 280: 605-613.
10. Rossouw JE, Anderson GL, Prentice RL, et al. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-333.
11. El Khoudary SR, Wildman RP, Matthews K, et al. Endogenous sex hormones impact the progression of subclinical atherosclerosis in women during the menopausal transition. Atherosclerosis 2012; 225: 180-186.
12. Celestino Catão Da Silva D, Nogueira De Almeida Vasconcelos A, Cleto Maria Cerqueira J, et al. Endogenous sex hormones are not associated with subclinical atherosclerosis in menopausal women. Minerva Ginecol 2013; 65: 297-302.
13. Naessen T, Bergquist J, Lind L, et al. Higher endogenous estrogen levels in 70-year-old women and men: An endogenous response to counteract developing atherosclerosis? Menopause 2012; 19: 1322-1328.
14. Ouyang P, Vaidya D, Dobs A, et al. Sex hormone levels and subclinical atherosclerosis in postmenopausal women: The multi-ethnic study of atherosclerosis. Atherosclerosis 2009; 204: 255-261.
15. Karim R, Hodis HN, Stanczyk FZ, et al. Relationship between serum levels of sex hormones and progression of subclinical atherosclerosis in postmenopausal women. J Clin Endocrinol Metab 2008; 93: 131-138.
16. Golden SH, Maguire A, Ding J, et al. Endogenous postmenopausal hormones and carotid atherosclerosis: A case-control study of the atherosclerosis risk in communities cohort. Am J Epidemiol 2002; 155: 437-445.
17. Munir JA, Wu H, Bauer K, et al. The perimenopausal atherosclerosis transition: Relationships between calcified and noncalcified coronary, aortic, and carotid atherosclerosis and risk factors and hormone levels. Menopause 2012; 19: 10-15.
18. Jeon GH, Kim SH, Yun SC, et al. Association between serum estradiol level and coronary artery calcification in postmenopausal women. Menopause 2010; 17: 902-907.
19. Hale GE, Hughes CL, Burger HG, et al. Atypical estradiol secretion and ovulation patterns caused by luteal out-of-phase (LOOP) events underlying irregular ovulatory menstrual cycles in the menopausal transition. Menopause 2009; 16: 50-59.
20. Tepper PG, Randolph JF Jr, McConnell DS, et al. Trajectory clustering of estradiol and follicle-stimulating hormone during the menopausal transition among women in the Study of Women's Health across the Nation (SWAN). J Clin Endocrinol Metab 2012; 97: 2872-2880.
21. Stein JH, Korcarz CE, Hurst RT, et al.American Society of Echocardiography Carotid Intima-Media Thickness Task Force,. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: A consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force endorsed by the Society for Vascular Medicine. J Am Soc Echocardiogr 2008; 21: 93-111.
22. Jensen-Urstad K, Jensen-Urstad M, Johansson J,. Carotid artery diameter correlates with risk factors for cardiovascular disease in a population of 55-year-old subjects. Stroke 1999; 30: 1572-1576.
23. Eigenbrodt ML, Sukhija R, Rose KM, et al. Common carotid artery wall thickness and external diameter as predictors of prevalent and incident cardiac events in a large population study. Cardiovasc Ultrasound 2007; 5: 1-11.
24. Sowers M, Crawford S, Sternfeld B, et al.SWAN: A multicenter, multiethnic, community-based cohort study of women and the menopausal transition. In: Lobo RA, Kelsey J, Marcus R, et al.(eds). Menopause: Biology and pathology, New York: Academic Press, 2000, pp. 175-188.
25. Wendelhag I, Gustavsson T, Suurküla M, et al. Ultrasound measurement of wall thickness in the carotid artery: Fundamental principles and description of a computerized analysing system. Clin Physiol 1991; 11: 565-577.
26. Thompson T, Sutton-Tyrrell K, Wildman RP, et al. Progression of carotid intima-media thickness and plaque in women with systemic lupus erythematosus. Arthritis Rheum 2008; 58: 835-842.
27. Sutton-Tyrrell K, Wolfson SK Jr, Thompson T, et al. Measurement variability in duplex scan assessment of carotid atherosclerosis. Stroke 1992; 23: 215-220.
28. England BG, Parsons GH, Possley RM, et al. Ultrasensitive semiautomated chemiluminescent immunoassay for estradiol. Clinical Chemistry 2002; 48: 1584-1586.
29. Sternfeld B, Ainsworth BE, Quesenberry CP,. Physical activity patterns in a diverse population of women. Prev Med 1999; 28: 313-323.
30. Steiner P, Freidel J, Bremner W, et al. Standardization of micro-methods for plasma cholesterol, triglyceride and HDL-cholesterol with the lipid research clinics' methodology. J Clin Chem Clin Biochem 1981; 19: 850A-850A.
31. Izawa S, Okada M, Matsui H, et al. A new direct method for measuring HDL cholesterol which does not produce any biased values. J Med Pharm Sci 1997; 37: 1385-1388.
32. Friedewald WT, Levy RI, Frederickson DS,. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparation ultracentrifuge. Clin Chem 1972; 18: 499-502.
33. Matthews D, Hosker J, Rudenski A, et al. Homeostasis model assessment: Insulin resistance and b cell function from fasting plasma glucose and insulin concentration in man. Diabetologia 1985; 28: 412-419.
34. Nagin DS, Odgers CL,. Group-based trajectory modeling in clinical research. Annu Rev Clin Psychol 2010; 6: 109-138.
35. Mendelsohn ME,. Protective effects of estrogen on the cardiovascular system. Am J Cardiol 2002; 89: 12E-17E. discussion 17E-18E.
36. Bairey Merz CN1, Johnson BD, Sharaf BL, et al.Study Group WISE,. Hypoestrogenemia of hypothalamic origin and coronary artery disease in premenopausal women: A report from the NHLBI-sponsored WISE study. J Am Coll Cardiol 2003; 41: 413-419.
37. Golden SH, Dobs AS, Vaidya D, et al. Endogenous sex hormones and glucose tolerance status in postmenopausal women. J Clin Endocrinol Metab 2007; 92: 1289-1295.
38. Folsom AR, Golden SH, Boland LL, et al. Association of endogenous hormones with C-reactive protein, fibrinogen, and white blood count in post-menopausal women. Eur J Epidemiol 2005; 20: 1015-1022.
39. Lambrinoudaki I, Christodoulakos G, Rizos D, et al. Endogenous sex hormones and risk factors for atherosclerosis in healthy Greek postmenopausal women. Eur J Endocrinol 2006; 154: 907-916.
40. Vaidya D, Dobs A, Gapstur SM, et al. The association of endogenous sex hormones with lipoprotein subfraction profile in the Multi-Ethnic Study of Atherosclerosis. Metabolism 2008; 57: 782-790.
41. Naessen T, Sjogren U, Bergquist J, et al. Endogenous steroids measured by high-specificity liquid chromatography-tandem mass spectrometry and prevalent cardiovascular disease in 70-year-old men and women. J Clin Endocrinol Metab 2010; 95: 1889-1897.
42. Labrie F,. Intracrinology. Mol Cell Endocrinol 1991; 78: C113-C118.